FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including:
• The significance of the study in the context of recent FDA approvals and treatment advancements.
• Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab.
• The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes.
• Management of side effects and clinical pearls for practitioners.

We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions.

Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, share, and subscribe for more practice-changing updates in oncology!

#MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology